Investors
Featured Press Release
Abstracts to be presented cover preclinical data on RYANODEX® (dantrolene sodium) for injectable suspension in Acute Radiation Syndrome and Traumatic Brain Injury WOODCLIFF LAKE, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today
See More
Total revenue for Q1 2023 was $66.3 million, compared to $115.9 million in Q1 2022 Q1 2023 net income was $0.44 per basic and diluted share and adjusted non-GAAP net income 1 was $1.27 per basic and $1.26 per diluted share Q1 2023 adjusted non-GAAP EBITDA of $22.3 million Q1 2023 net sales of
See More
Eagle Pharmaceuticals Granted Unique J-Code for Byfavo®¹ (remimazolam for injection) from CMS
5/1/23
-- Byfavo 1 is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less WOODCLIFF LAKE, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Centers
See More
Upcoming Events & Presentations
No items found.